Using this technology, delivery of KRASG12D-specific siRNA clearly dampened KRAS expression and inhibited the in vivo growth of pancreatic tumors in both subcutaneous and orthotopic mouse models [37]. The gene discussed is KRAS; the disease is pancreatic neoplasm.